Brind.

BioCryst focuses on rare diseases like Hereditary Angioedema (HAE), and Dr. Helen Thackray led R&D efforts at the company.

Steady: 0 in the last 7 days Updated sep 23

The latest in this situation

  1. Pending applications for market expansion in Europe and Canada for ORLADEYO.

How it started

1 report, 1 independent, last reported Aug 11. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

BioCryst focuses on rare diseases like Hereditary Angioedema (HAE), and Dr. Helen Thackray led R&D efforts at the company.

Who's involved

What this event is mainly about
BioCryst Pharmaceuticals

How it developed

Newest first. Tap a step to see who reported it.
  1. AscellaHealth supports rare disease manufacturers, while BioCryst Pharmaceuticals details its leadership structure with Quill, Gayer, and Oldham.Sub-event
  2. ORLADEYO has seen significant revenue growth, and new treatments are being evaluated for their potential impact on the demand for HAE sufferers.Sub-event
  3. BioCryst focuses on HAE, and Dr. Thackray led R&D efforts there.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireBioCryst Announces Departure of Dr. Helen Thackray RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackra